4502 — Takeda Pharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00
- ¥7tn
- ¥11tn
- ¥4tn
- 37
- 54
- 66
- 53
C2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 725,819 | 653,436 | 1,002,820 | 875,000 | 553,704 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 749,119 | 784,921 | 812,714 | 724,377 | 681,693 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 2,993,037 | 2,469,432 | 2,712,893 | 2,593,642 | 2,397,956 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,331,931 | 1,386,370 | 1,453,917 | 1,582,800 | 1,691,229 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 13,792,773 | 12,821,094 | 12,912,293 | 13,178,018 | 13,957,750 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2,553,049 | 2,175,898 | 1,773,176 | 2,145,730 | 2,481,940 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 8,610,788 | 8,097,611 | 7,739,256 | 7,494,999 | 7,603,627 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 5,181,985 | 4,723,483 | 5,173,037 | 5,683,019 | 6,354,123 |
Total Liabilities & Shareholders' Equity | 13,792,773 | 12,821,094 | 12,912,293 | 13,178,018 | 13,957,750 |
Total Common Shares Outstanding |